Lv2
118 积分 2022-12-06 加入
A systematic review of various pKa determination techniques
5天前
已完结
Beyond cytotoxic potency: disposition features required to design ADC payload
26天前
已完结
Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE
26天前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
1个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
1个月前
已完结
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
2个月前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
3个月前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
3个月前
已完结
In vivo CAR T cell generation to treat cancer and autoimmune disease
5个月前
已完结
皖公网安备34019202002308
